Trials / Completed
CompletedNCT04720183
Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects
A Phase 1, Fixed Sequence, Open-label, Drug-drug Interaction Study to Evaluate the Effect of GLPG3970 on the Pharmacokinetics of Sulfasalazine in Adult, Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
GLPG3970 will be given with sulfasalazine to investigate the effect of co-administration on the pharmacokinetics of sulfasalazine, and on the safety and tolerability of the drugs in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sulfasalazine | On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state. |
| DRUG | GLPG3970 | On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state. |
Timeline
- Start date
- 2021-01-11
- Primary completion
- 2021-04-21
- Completion
- 2021-04-23
- First posted
- 2021-01-22
- Last updated
- 2024-09-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04720183. Inclusion in this directory is not an endorsement.